Research Paper Volume 13, Issue 3 pp 3945—3956

MicroRNA-205-5p targets the HOXD9-Snail1 axis to inhibit triple negative breast cancer cell proliferation and chemoresistance

Effect of miR-205 on chemotherapy sensitivity of TNBC cells. (A) Cell proliferation analysis of Cisplatin in miR-205 overexpression treatment in MDA-MB-231 cells. (B) Cell proliferation analysis of Cisplatin in miR-205 knockdown treatment in BT-549 cells. (C) Cell proliferation analysis of Doxorubicin in miR-205 overexpression treatment in MDA-MB-231 cells. (D) Cell proliferation analysis of Doxorubicin in miR-205 knockdown treatment in BT-549 cells. (E) Cell proliferation analysis of Paclitaxel in miR-205 overexpression treatment in MDA-MB-231 cells. (F) Cell proliferation analysis of Paclitaxel in miR-205 knockdown treatment in BT-549 cells. ***P

Figure 3. Effect of miR-205 on chemotherapy sensitivity of TNBC cells. (A) Cell proliferation analysis of Cisplatin in miR-205 overexpression treatment in MDA-MB-231 cells. (B) Cell proliferation analysis of Cisplatin in miR-205 knockdown treatment in BT-549 cells. (C) Cell proliferation analysis of Doxorubicin in miR-205 overexpression treatment in MDA-MB-231 cells. (D) Cell proliferation analysis of Doxorubicin in miR-205 knockdown treatment in BT-549 cells. (E) Cell proliferation analysis of Paclitaxel in miR-205 overexpression treatment in MDA-MB-231 cells. (F) Cell proliferation analysis of Paclitaxel in miR-205 knockdown treatment in BT-549 cells. ***P<0.001.